Schedule of Segment Reporting |
Reporting by segment is summarized as follows:
Amount in USD | |
For the six months ended June 30, 2025 | | |
For the six months ended June 30, 2024 | |
| |
Biotechnology | | |
Pharmaceutical | | |
Total | | |
Biotechnology | | |
Pharmaceutical | | |
Total | |
Revenues | |
$ | — | | |
$ | 248,536 | | |
$ | 248,536 | | |
$ | — | | |
$ | 110,990 | | |
$ | 110,990 | |
Gross margin | |
| — | | |
| 178,655 | | |
| 178,655 | | |
| — | | |
| 95,124 | | |
| 95,124 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Depreciation and amortization | |
| 6,491 | | |
| — | | |
| 6,491 | | |
| 9,056 | | |
| — | | |
| 9,056 | |
Selling, general and administrative | |
| 484,739 | | |
| 40,281 | | |
| 525,020 | | |
| 363,801 | | |
| 40,574 | | |
| 404,375 | |
Research and development | |
| 144,776 | | |
| 25,553 | | |
| 170,329 | | |
| 124,600 | | |
| 26,449 | | |
| 151,049 | |
Total Operating expenses | |
| 636,006 | | |
| 65,834 | | |
| 701,840 | | |
| 497,457 | | |
| 67,023 | | |
| 564,480 | |
Other expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (111,093 | ) | |
| — | | |
| (111,093 | ) | |
| (107,487 | ) | |
| — | | |
| (107,487 | ) |
Fair value adjustment | |
| 30,511 | | |
| — | | |
| 30,511 | | |
| (17,996 | ) | |
| — | | |
| (17,996 | ) |
Other income (loss), net | |
| 1,035 | | |
| — | | |
| 1,035 | | |
| 1,707 | | |
| — | | |
| 1,707 | |
Other expenses | |
| (79,547 | ) | |
| — | | |
| (79,547 | ) | |
| (123,776 | ) | |
| — | | |
| (123,776 | ) |
Net income | |
$ | (715,553 | ) | |
$ | 112,821 | | |
$ | (602,732 | ) | |
$ | (621,233 | ) | |
$ | (28,101 | ) | |
$ | (593,132 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Assets of segment | |
$ | 1,625,478 | | |
$ | 341 | | |
$ | 1,625,819 | | |
$ | 1,375,638 | | |
$ | 3,130 | | |
$ | 1,378,768 | |
|
Schedule of Revenue |
Revenues for the six months ended June 30, 2025, and 2024 are summarized as follows:
| |
Six months
ending | | |
Six months
ending | |
| |
June 30,
2025 | | |
June 30, 2024 | |
Service fee for arrangements for sale of Dandruff products | |
$ | - | | |
$ | 75,147 | |
Licensing and milestone fees – Luliconazole | |
| 116,900 | | |
| - | |
Sale of products | |
| 121,424 | | |
| 28,113 | |
Royalty income related to above product sales | |
| 10,212 | | |
| 7,730 | |
Total | |
$ | 248,536 | | |
$ | 110,990 | |
|